Soligenix Inc. (NASDAQ: SNGX) announced that its Phase 3 FLASH2 trial evaluating HyBryte for cutaneous T-cell lymphoma treatment was halted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE